Latest Breaking News On - Trishna goswami - Page 1 : comparemela.com

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

100% of treated leukemia patients achieved durable complete remission at 1-year, including high-risk and relapsed acute myeloid leukemia patients who had previously failed multiple lines of.

United statesTrishna goswamiGlenn schulmanJosephp mcguirkDrug administrationExchange commissionGlobenewswire incUniversity of kansas cancer centerEuropean hematology associationHematology associationDose levelChief medical officerSpeas professorDivision directorHematologic malignanciesCellular therapeutics

Encouraging Phase 1 data for glioblastoma treatment

Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio s genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma.

United statesTrishna goswamiLarry lambBurt naborsMina lobbousAmerican society of clinical oncologyOneal comprehensive cancer centerL harbert institute for innovationO neal comprehensive cancer centerMedicine departmentClinical oncologyAnnual meetingCleveland clinic

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Trishna goswamiJosephp mcguirkGlenn schulmanEuropean hematology association congressEuropean hematology associationUniversity of kansas cancer centerExchange commissionCompany contactAnnounces upcoming presentationHematology associationChief medical officerPilot studyDonor derivedSchutte speas professorDivision directorHematologic malignancies

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

United statesTrishna goswamiPatrick mccallJoseph mcguirkAmerican society of hematologyUniversity of kansas cancer centerCompany contactExchange commissionAmerican societyAnnual meetingDose levelChief medical officerSchutte speas professorDivision directorHematological malignanciesCellular therapeutics

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomBritish columbiaUnited statesMina lobbousTrishna goswamiBurt naborsUniversity of louisvilleCompany contactUniversity of alabama at birminghamsession nameExchange commissionHeersink school of medicineSociety for neuroInc patrick mccallAnnual meetingChief medical officerGene modified autologous gamma delta